Skip to Content

Generic Ritalin LA Availability

See also: Generic Ritalin

Ritalin LA is a brand name of methylphenidate, approved by the FDA in the following formulation(s):

RITALIN LA (methylphenidate hydrochloride - capsule, extended release;oral)

  • Manufacturer: NOVARTIS
    Approval date: June 5, 2002
    Strength(s): 20MG [RLD] [AB1], 30MG [RLD] [AB1], 40MG [RLD] [AB1]
  • Manufacturer: NOVARTIS
    Approval date: April 10, 2004
    Strength(s): 10MG [RLD] [AB1]
  • Manufacturer: NOVARTIS
    Approval date: October 27, 2014
    Strength(s): 60MG [RLD]

Has a generic version of Ritalin LA been approved?

A generic version of Ritalin LA has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Ritalin LA and have been approved by the FDA:

methylphenidate hydrochloride capsule, extended release;oral

  • Manufacturer: BARR LABS INC
    Approval date: July 13, 2012
    Strength(s): 20MG [AB1], 30MG [AB1], 40MG [AB1]
  • Manufacturer: BARR LABS INC
    Approval date: October 15, 2014
    Strength(s): 10MG [AB1]
  • Manufacturer: MAYNE PHARMA
    Approval date: December 1, 2011
    Strength(s): 20MG [AB1], 30MG [AB1], 40MG [AB1]
  • Manufacturer: MAYNE PHARMA
    Approval date: February 26, 2018
    Strength(s): 10MG [AB1]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ritalin LA. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Multiparticulate modified release composition
    Patent 6,228,398
    Issued: May 8, 2001
    Inventor(s): Devane; John G. & Stark; Paul & Fanning; Niall M. M.
    Assignee(s): Elan Corporation, PLC

    The invention relates to a multiparticulate modified release composition that in operation delivers an active ingredient in a pulsed or bimodal manner. The multiparticulate modified release composition comprises an immediate release component and a modified release component; the immediate release component comprising a first population of active ingredient containing particles and the modified release component compnsimg a second population of active ingredient containing particles coated with a controlled release coating; wherein the combination of the immediate release and modified release components in operation deliver the active ingredient in a pulsed or a bimodal manner. The invention also relates to a solid oral dosage form containing such a multiparticulate modified release composition. The plasma profile achieved by the multiparticulate modified release composition is advantageous in reducing patient tolerance to the active ingredient and in increasing patient compliance by reducing dosage frequency.

    Patent expiration dates:

    • November 1, 2019
      Drug product

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
ABProducts meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.